Introduction
During the past few years the cytogenetic effects of an increasing number of psychotropic agents have been investigated (Cohen et al., 1967; Cohen et al., 1969; Nielsen et al., 1969; Schmid and Staiger, 1969; Staiger, 1969; Stenchever and Frankel, 1969) . Simple explanations for the apparent conflicting observations obtained with some drugs are exceedingly difficult to propose, but such factors as observer differences and differences in tissue culture medium, culture time, and technique have been suggested. This report assesses the possible induction of in-vivo chromosomal damage by two psychotropic agents (perphenazine and chlorpromazine) which have previously been implicated as "chromosome breakers" (Cohen et al., 1967; Nielsen et al., 1969) . The experiment was designed to test for differences between the procedures used in two different cytogenetic laboratories.
Materials and Methods
Nineteen drug-treated male subjects aged 23-63 years were studied. They were patients at the Neuropsychiatric Institute, Princeton, New Jersey. All had histories of chronic schizophrenic reactions of various types, and all had received daily doses of standard and investigational drugs for up to two years before the experiment began. Perphenazine was given to nine patients in increasing doses over a six-week period. Daily doses were increased every two days, ranging from 8 mg/day to a maximum of 48 mg/day. The average total dose per patient was 1,110 mg during the six-week period.
Chlorpromazine was given to 10 patients. The daily dose range was increased from 150 mg to 600 mg/day at about two-day intervals during the six-week study. Average total dose per patient was 18,565 mg.
Six normal males were selected as controls from hospital personnel with no history of previous drug ingestion who worked on the same wards as the patients.
During the course of this study none of the volunteers or patients needed radiological procedures or suffered any intercurrent illness or viral infections.
Experimental Design.-Drugs were discontinued in all cases for one month before the study began (washout, period 1).
Blood samples were obtained for chromosome analysis at the beginning of the washout phase and again at its completion (baseline, period 2). Similar samples were then obtained after three (period 3) and six (period 4) weeks of daily drug ingestion. At the completion of period 4 all drugs were withheld for up to one month, and a final blood sample was obtained (period 5) before reinstitution of therapy.
Chromosome Preparations.-Blood samples were collected in heparinized syringes which were numerically coded. Three to five drops of whole blood was inoculated into each of four microculture tubes (chromosome medium 1A, GIBCO). Two tubes were sent to each of the participating cytogenetics laboratories (New York City and Buffalo) for culture and analysis. The same batch of medium was used throughout the study. Similar procedures of culture, harvesting, slide preparation, and scoring were used in both laboratories. The cultures were incubated at 37°C for 72 hours, the final two hours in the presence of Colcemid (demecolcine) (0 5 ,ug/ml) or Velban (vinblastine sulphate) (0 05 j±g/ml). The cultures were harvested after a slight modification of the method of Moorhead et al. (1960) . After centrifugation the supernate was discarded and the cells were resuspended in hypotonic sodium citrate (1 %) or fetal calf serum in distilled water (1: 5) for 15 min at 37°C. The cells were then fixed in several changes (10 min each) of the 3 : 1 methanol: glacial acetic acid fixative. Two drops of cell suspension were then placed on a chilled, prewet (either distilled water or 70% methanol) microscope slide and passed through a flame for ignition. The slides were stained in 2% acetic orcein or Giemsa and dehydrated in a graduated series of alcohol, and a coverslip was mounted with Permount. The data on total abnormal cells given in the Table include all abnormalities-for example, gaps, simple breaks, and rearrangements. No significant differences were noted among the various drug groups or between laboratories (P > 0.25). The findings were similar for the various individual abnormalities scored-that is, gaps alone (P > 0-25) and breaks (P > 0-25). A total of 14 structural rearrangements were observed-seven dicentrics, three rings, and four triradials and quadriradials (see Fig.) . These abnormalities were seen in both controls and treated patients.
There was no difference in the rate of cell division between the patients and the controls (see Table) . The Frequency of Total Abnormal CeUs/1OO Cells Controls ..6-33 ± 152
5-08 ± 1-22 3 50 + 109 4 00 ± 1-41 3-83 ± 0 99
Perphenazinne.
6-61 ± 110 5-00 ± 1-03 406 ±1-00 4-83 ± 1-17 5-14 + 1-28 Chlorpromazine .
6-30 _1-08 one-month period without medication. This reduction, however, was apparent in the controls as well as in the patients receiving the drugs and was obvious in both laboratories.
Discussion
Reports of the chromosome-breaking potential of various drugs have evoked much concern, with particular attention paid to those psychotropic compounds (including hallucinogens) reportedly having this capability. Nonetheless, relatively few well-controlled in-vivo prospective studies have been performed to investigate these properties. In the present investigation an attempt was made to obtain baseline values of chromosome damage in the subjects before the actual investigation began. An additional feature of this double-blind study was the simultaneous culturing and scoring of replicate samples from each subject in two independent cytogenetic laboratories. The results were completely negative for both drugs tested and there was no statistically significant difference between the laboratories for any value scored. The method of culturing, harvesting, and scoring of the cells was similar although not identical in both laboratories, and therefore results tested the repeatability and reliability of such procedures. Our negative findings indicate that neither perphenazine nor chlorpromazine has chromosome-breakage potential. This is in contrast to the findings of Nielsen et al. (1969) , which indicated that perphenazine could perhaps induce chromosome damage. That study, however, contained several possible biases. Firstly, no systematic attempt was made to obtain baseline values of chromosome damage in the subjects studied. More importantly, those patients receiving perphenazine also received orphenadrine. The chromosome-breaking potential of orphenadrine was not examined, yet Nielsen et al. attributed the positive effect seen to perphenazine, not considering any possible effects of orphenadrine or a synergism between the two agents administered. Orphenadrine was not studied in the present experiment since its administration was not clinically justifiable. The lack of chromosome damage induced by perphenazine, however, suggests that orphenadrine may have been the active agent in the studies of Nielsen et al. (1969) . On the other hand the present studies confirmed the previous negative studies of others concerning chlorpromazine. Cohen et al. (1969) studied this drug in vitro and in vivo with negative results, as did Sandberg in a double-blind study of 35 schizophrenic patients (personal communication). Therefore none of the psychotropic drugs tested for the induction of cytogenetic damage has clearly shown such potential.
